about
ATM-mediated phosphorylation activates the tumor-suppressive function of B56γ-PP2AA PP2A phosphatase high density interaction network identifies a novel striatin-interacting phosphatase and kinase complex linked to the cerebral cavernous malformation 3 (CCM3) proteinPME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant gliomaPP4R4/KIAA1622 forms a novel stable cytosolic complex with phosphoprotein phosphatase 4Over expression of PPP2R2C inhibits human glioma cells growth through the suppression of mTOR pathwayProtein Phosphatase 2A as a Therapeutic Target in Acute Myeloid LeukemiaStructural bases for recognition of Anp32/LANP proteinsStructure of a Protein Phosphatase 2A Holoenzyme: Insights into B55-Mediated Tau DephosphorylationPP2A: The Wolf in Sheep's Clothing?Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cellsComputer-aided targeting of the PI3K/Akt/mTOR pathway: toxicity reduction and therapeutic opportunitiesCritical role of heat shock protein 27 in bufalin-induced apoptosis in human osteosarcomas: a proteomic-based researchProtein phosphatase 2A promotes the transition to G0 during terminal differentiation in DrosophilaProtein phosphatase 2A subunit gene haplotypes and proliferative breast disease modify breast cancer risk.Physiological regulation of Akt activity and stability.A specific form of phospho protein phosphatase 2 regulates anaphase-promoting complex/cyclosome association with spindle poles.MicroRNA-135a-3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer.Interaction between salt-inducible kinase 2 and protein phosphatase 2A regulates the activity of calcium/calmodulin-dependent protein kinase I and protein phosphatase methylesterase-1.Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.PMC, a potent hydrophilic α-tocopherol derivative, inhibits NF-κB activation via PP2A but not IκBα-dependent signals in vascular smooth muscle cells.Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer.Germline variation in TP53 regulatory network genes associates with breast cancer survival and treatment outcome.Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E.A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.PP2A:B56{epsilon}, a substrate of caspase-3, regulates p53-dependent and p53-independent apoptosis during development.Inhibition of protein phosphatase 2A with a small molecule LB100 radiosensitizes nasopharyngeal carcinoma xenografts by inducing mitotic catastrophe and blocking DNA damage repair.Merkel cell polyomavirus small T antigen is oncogenic in transgenic mice.Survival of cancer stem cells under hypoxia and serum depletion via decrease in PP2A activity and activation of p38-MAPKAPK2-Hsp27.The Natural cAMP Elevating Compound Forskolin in Cancer Therapy: Is It Time?Protein phosphatase 2A catalytic subunit α (PP2Acα) maintains survival of committed erythroid cells in fetal liver erythropoiesis through the STAT5 pathway.MYC-dependent regulation and prognostic role of CIP2A in gastric cancer.Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cellsLessons in signaling and tumorigenesis from polyomavirus middle T antigen.Microcystin-LR (MCLR) induces a compensation of PP2A activity mediated by α4 protein in HEK293 cells.Ligand-directed targeting of lymphatic vessels uncovers mechanistic insights in melanoma metastasisHuman cancer-associated mutations in the Aα subunit of protein phosphatase 2A increase lung cancer incidence in Aα knock-in and knockout mice.Prognostic role of CIP2A expression in serous ovarian cancerPhosphatases: the new brakes for cancer development?PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effectsProtein phosphatase 2A (PP2A) is increased in old murine B cells and mediates p38 MAPK/tristetraprolin dephosphorylation and E47 mRNA instability.
P2860
Q24298893-D6471911-A11C-436C-8139-6D38BAE77372Q24311685-730F5998-309E-436B-A07F-02EF19E2B2B3Q24322118-BC1EBE5F-DE7B-4481-A422-C18665F2C6A0Q24324592-E1A4BE2B-67B6-49A2-BC24-1B8FA26E3A5CQ24338396-371FCCC7-4D5F-4EA9-B415-258F4262B79CQ26752430-7F796DE1-01A1-4BE7-AFA4-1CC723DAA8ACQ27650321-FC232BEE-C5CC-428D-A216-12F87146C9E6Q27652517-653428EB-8F47-4C8E-94C5-712C0B5D0CDEQ28088747-8AA73A1F-B512-4501-A6ED-BE61843EC79BQ28299365-B68E8323-04A4-413A-B9C1-B94D7281ABF3Q28397537-03A3040F-1528-4950-A508-A9D95994C9A7Q28484427-D9DFED40-E188-4D6C-8DE3-9B3BE14B19B9Q30375159-42683241-32FC-4BC5-BF43-B223EE97FA57Q33596201-1215A32A-160A-413C-B861-9D2AECF6A2EBQ33680673-CFFF95C7-6565-4694-B24B-B665DD2D9C24Q33721223-8D41BF5C-F0E5-48BE-8F34-DE36FE75B637Q33738954-57F1E25D-038D-4D0D-BE57-183992EB2CBDQ33947256-33F545AC-A923-4B89-824F-494F8608E800Q34007879-48E8A7E9-B843-4BD0-947A-DE62B1297695Q34011446-418F3F1D-D0A8-4641-B130-EF38793EBAC4Q34051988-93FBF8F7-2F1C-43A0-B959-52FA8B3CAB71Q34158129-696BB4AC-F399-4DE4-A9CF-9418A2A9AC6AQ34177252-5C9BE8B4-D730-48B4-9DBF-F69AE5C303C8Q34220013-FA4FA2B5-527D-4E32-951C-60DCB5DCA2DEQ34251140-B5D61191-E577-43C3-9F81-50223B4E6656Q34365755-83D1BBF5-F215-44DB-B60C-388E7B8EE471Q34443490-6BC696D6-02A7-4737-9047-6524DCD14F76Q34490253-99B5B557-88E7-42EE-8578-AB04DCDF7AA2Q34542598-8661BDC2-C5FB-4040-B967-5CDDC520A65FQ34838835-12573AFF-F4B5-43CC-A839-3514275B84E5Q34983172-4F47AC82-A36D-4D9F-9AD1-BD89D84CB3E4Q35000235-673AEDE6-1597-49DB-A78C-49FC990FA224Q35000523-BF593A57-9D1F-4014-BD36-E19450AE7E61Q35059243-7E5A24B7-7A46-477B-9677-3036D01274C3Q35134617-025C0D55-807B-47ED-A94E-10EBE40F6258Q35192607-EEADFC6E-ABC3-4870-8762-BAFD612D3373Q35263210-0A760FDE-B151-4B0D-B8B6-5C361082E9E0Q35504084-37C352F2-1D48-44ED-AAD4-A338FF969354Q35552005-32C888D7-4114-4624-B55C-BE6B1F1C0F04Q35571154-FED9572D-BD69-48F1-9A57-C0E440819117
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
PP2A: unveiling a reluctant tumor suppressor.
@ast
PP2A: unveiling a reluctant tumor suppressor.
@en
PP2A: unveiling a reluctant tumor suppressor.
@nl
type
label
PP2A: unveiling a reluctant tumor suppressor.
@ast
PP2A: unveiling a reluctant tumor suppressor.
@en
PP2A: unveiling a reluctant tumor suppressor.
@nl
prefLabel
PP2A: unveiling a reluctant tumor suppressor.
@ast
PP2A: unveiling a reluctant tumor suppressor.
@en
PP2A: unveiling a reluctant tumor suppressor.
@nl
P1433
P1476
PP2A: unveiling a reluctant tumor suppressor.
@en
P2093
Marc Mumby
P356
10.1016/J.CELL.2007.06.034
P407
P577
2007-07-01T00:00:00Z